Jacob Leach - DexCom Ex COO
| DC4 Stock | EUR 73.98 0.63 0.86% |
Insider
Jacob Leach is Ex COO of DexCom Inc
| Age | 45 |
| Phone | 858 200 0200 |
| Web | https://www.dexcom.com |
Jacob Leach Latest Insider Activity
Tracking and analyzing the buying and selling activities of Jacob Leach against DexCom stock is an integral part of due diligence when investing in DexCom. Jacob Leach insider activity provides valuable insight into whether DexCom is net buyers or sellers over its current business cycle. Note, DexCom insiders must abide by specific rules, including filing SEC forms every time they buy or sell DexCom'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Jacob Leach over six months ago Disposition of 2932 shares by Jacob Leach of DexCom at 121.8505 subject to Rule 16b-3 |
DexCom Management Efficiency
The company has return on total asset (ROA) of 0.0474 % which means that it generated a profit of $0.0474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1635 %, meaning that it generated $0.1635 on every $100 dollars invested by stockholders. DexCom's management efficiency ratios could be used to measure how well DexCom manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | INSIDER Age | ||
| OAM OAM | CarsalesCom | 73 | |
| Kane Hocking | CarsalesCom | N/A | |
| Martin Hughes | The Hanover Insurance | 69 | |
| Matthew Mitchell | The Hanover Insurance | N/A | |
| James Kelley | The Hanover Insurance | N/A | |
| Jennifer Luisa | The Hanover Insurance | N/A | |
| William Elliott | CarsalesCom | N/A | |
| Lindsay Greenfield | The Hanover Insurance | N/A | |
| Willard Lee | The Hanover Insurance | 53 | |
| Sarah Medina | The Hanover Insurance | N/A | |
| Theodore Bunting | The Hanover Insurance | 60 | |
| Scott Grieco | The Hanover Insurance | N/A | |
| P Condron | The Hanover Insurance | 73 | |
| Gayle Falvey | The Hanover Insurance | N/A | |
| Dennis Kerrigan | The Hanover Insurance | 58 | |
| Denise Lowsley | The Hanover Insurance | 47 | |
Management Performance
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0474 |
DexCom Inc Leadership Team
Elected by the shareholders, the DexCom's board of directors comprises two types of representatives: DexCom inside directors who are chosen from within the company, and outside directors, selected externally and held independent of DexCom. The board's role is to monitor DexCom's management team and ensure that shareholders' interests are well served. DexCom's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, DexCom's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kevin Sayer, CEO Chairman | ||
| Matthew Dolan, Corp Strategy | ||
| Michael Brown, Ex Officer | ||
| Jacob Leach, Ex COO | ||
| Sadie Stern, Ex Officer | ||
| Jereme Sylvain, CFO VP | ||
| Sean Christensen, Director Relations | ||
| Steven Pacelli, Ex Ventures | ||
| Andrew Balo, Access Affairs | ||
| Paul Flynn, Ex Revenue |
DexCom Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is DexCom a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.16 | |||
| Return On Asset | 0.0474 | |||
| Profit Margin | 0.12 % | |||
| Operating Margin | 0.13 % | |||
| Current Valuation | 42.38 B | |||
| Shares Outstanding | 386.41 M | |||
| Shares Owned By Insiders | 0.42 % | |||
| Shares Owned By Institutions | 99.58 % | |||
| Price To Earning | 191.84 X | |||
| Price To Book | 24.95 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in DexCom Stock
When determining whether DexCom Inc is a strong investment it is important to analyze DexCom's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact DexCom's future performance. For an informed investment choice regarding DexCom Stock, refer to the following important reports:Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in DexCom Inc. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Equity Valuation module to check real value of public entities based on technical and fundamental data.